Arena Pharmaceuticals, Inc. ARNA revealed Wednesday financial results for the fourth quarter and full year ended Dec. 31, 2021.
Q4 Finanical HIghlights
- Net loss for the fourth quarter was $155.6 million compared to a net loss of $122.2 million for the same period in 2020
- Basic and diluted net loss per share for the fourth quarter was $2.54 compared to basic and diluted net loss per share of $2.10 for the same period in 2020
- Research and development (R&D) expenses for the fourth quarter totaled $110.3 million compared to $100.4 million in the same period in 2020. This increase was primarily driven by our advancing clinical studies, including the etrasimod Phase 3 program, as well as an increase in personnel expenses to support our clinical programs.
- Selling, general and administrative (SG&A) expenses for the fourth quarter totaled $34.5 million, compared to $34.9 million in the same period in 2020.
- Cash, cash equivalents and marketable securities were $700 million at December 31, 2021 as compared to $1.1 billion at December 31, 2020
Full Year 2021 Financial Results
- Revenues totaled $100,000
- Net loss was $616.4 million, or $10.14 per share
- Research and development expenses totaled $419.5 million, including $33.5 million related to non-cash share-based compensation
- Selling, general and administrative expenses totaled $126.2 million, including $36.9 million related to non-cash share-based compensation
-
Key Program & Corporate Updates
- In December pharmaceutical giant Pfizer Inc. PFE and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena
- In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn’s disease
- In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud’s phenomenon secondary to systemic sclerosis
- Phase 3 ELEVATE program for etrasimod in ulcerative colitis remains on track for topline data readout in Q1 2022
About Arena Pharmaceuticals
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!